Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Romiplostim - Amgen

Drug Profile

Romiplostim - Amgen

Alternative Names: AMG-531; Nplate; Romiplate

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kirin-Amgen
  • Class Antianaemics; Carrier proteins; Immunotherapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Thrombopoietin receptor agonists; Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic thrombocytopenic purpura
  • Registered Aplastic anaemia
  • Phase III Thrombocytopenia
  • Discontinued Myelodysplastic syndromes

Most Recent Events

  • 15 Nov 2019 Kyowa Kirin plans to file for regulatory approval for Aplastic anaemia in South Korea, in 2019-2020
  • 15 Nov 2019 Kyowa Kirin plans to file for regulatory approval for Idiopathic thrombocytopenic purpura in China, in 2020
  • 18 Oct 2019 Registered for Idiopathic thrombocytopenic purpura (In adults, Newly diagnosed) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top